The American Parkinson Disease Association (APDA) is funding a new APDA Center for Advanced Research at Yale University’s School of Medicine, the newest of nine such centers in its U.S. network, in recognition of the school’s work into the causes and the potential for personalized treatment of Parkinson’s…
Booster Therapeutics announced its launch and the start of work into therapeutics that improve the body’s ability to clear itself of the defective, disease-causing proteins that drive Parkinson’s disease and other neurodegenerative conditions. The company, which is based in Berlin and whose opening was supported by $15 million…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a second research grant of $2.5 million to Selonterra to advance the California-based company’s preclinical development of new therapeutic compounds targeting the genetic causes of Parkinson’s disease. Selonterra specifically will be testing whether compounds that…
Gain Therapeutics has presented new preclinical data showing GT-02287, its experimental therapy for Parkinson’s disease, can slow disease progression in mouse and cellular models of the disease. Overall, the treatment was shown to improve motor function and coordination, and activities of daily living in mouse models of Parkinson’s…
Researchers at New York University (NYU) Langone Health were awarded a two-year, $1.6 million grant by the National Institutes of Health (NIH) to investigate eye changes as potential early signs and progression markers of Parkinson’s disease and Alzheimer’s. The grant, given under the NIH Common Fund Venture Program’s…
Note: This story was updated Oct. 7, 2024, to correct references to the open-label extension study of the BounDNless trial. A year of treatment with ND0612, an investigational liquid formulation of levodopa/carbidopa continuously administered as an infusion under the skin, sustainably reduced the periods of time when motor symptoms…
Treatment with tavapadon as a fixed-dose single therapy significantly improved motor function in early stage Parkinson’s disease, according to top-line data from a completed Phase 3 trial. Full results from TEMPO-1 (NCT04201093) will be presented at future medical meetings and support regulatory submissions toward the investigational therapy’s approval.
A new mouse model replicates the symptoms of Parkinson’s disease and its progression in patients, beginning with diminished smell and other disease nonmotor symptoms that are early signs of the neurodegenerative disorder and often evident before problems with gait and balance arrive, scientists report. Many mouse models overexpress…
Crexont, an extended-release formulation of levodopa and carbidopa, is now available in pharmacies across the U.S. for people with Parkinson’s disease. The Parkinson’s therapy, marketed by Amneal Pharmaceuticals is designed to maintain steady levels of levodopa and carbidopa in the body, extending periods of optimal symptom management,…
SGLT2 inhibitors, which are a type of medication to treat diabetes, may reduce the risk for neurodegenerative conditions, including Parkinson’s disease and dementia, a study from South Korea suggests. The overall risk for developing dementia due to any cause and Parkinson’s was lower in patients taking SGLT2 inhibitors than…
Get regular updates to your inbox.
